RenovoRx Appoints Dr. Ramtin Agah as Executive Chairman with $450K Base Salary and Bonus Eligibility

summarizeSummary

RenovoRx appointed Dr. Ramtin Agah as Executive Chairman, formalizing an expanded strategic role and establishing a new compensation package including a $450,000 base salary and bonus eligibility.

check_boxKey Events

• Executive Chairman Appointment

  Dr. Ramtin Agah, previously Chief Medical Officer and Chairman of the Board, was formally appointed to the newly created position of Executive Chairman, effective February 27, 2026.

• New Compensation Package

  Dr. Agah will receive an annualized base salary of $450,000, effective January 1, 2026, and is eligible for an annual discretionary bonus of up to 40% of his base salary, plus annual equity grants.

• Expanded Strategic Responsibilities

  His new role includes leading clinical direction, active engagement in business development, assisting with investor communications, providing strategic leadership on regulatory interactions, and supporting sales and finance teams.

auto_awesomeAnalysis

RenovoRx has formalized a significant leadership role and compensation package for Dr. Ramtin Agah, elevating him to Executive Chairman while he retains his Chief Medical Officer duties. This move solidifies a key executive's position and expands his strategic responsibilities, including investor communications and business development, which are crucial for a life sciences company advancing clinical trials and commercialization. The substantial compensation package, including a $450,000 base salary and up to 40% bonus, represents a material financial commitment for a company of RenovoRx's size, signaling confidence in Dr. Agah's expanded role and the company's strategic direction. This follows recent positive news regarding a successful private placement and a clinical trial milestone, suggesting a concerted effort to strengthen leadership for future growth.